AstraZeneca plc (AZN) Ordinary US$0.25
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
AstraZeneca gets first US approval for cancer treatment Datroway
20 January 2025 07:30
(Sharecast News) - AstraZeneca announced on Monday that it has secured approval from the US Food and Drug Administration, alongside Daiichi Sankyo, for 'Datroway', or datopotamab deruxtecan, a...
-
AstraZeneca's rare cancer drug Calquence gets US regulatory nod
17 January 2025 07:13
(Sharecast News) - AstraZeneca has announced that its Calquence drug has been approved in the US when used alongside chemoimmunotherapy for patients with previously untreated mantle cell lymphoma (MCL).
-
London close: Stocks mixed in quiet post-Christmas trade
27 December 2024 14:38
(Sharecast News) - London markets closed on a mixed note Friday in subdued trading, as the ongoing holiday period kept activity light with little news to influence sentiment.
-
AstraZeneca pulls EU application for cancer drug
24 December 2024 07:09
(Sharecast News) - AstraZeneca has pulled its European marketing authorisation application for its non-small cell lung cancer treatment based on the results of a phase III trial.
-
AstraZeneca lung cancer drug Tagrisso approved by EU regulators
23 December 2024 07:17
(Sharecast News) - AstraZeneca's lung cancer treatment Tagrisso has been approved by European Union regulators on the back of "powerful results" from a phase III trial.
-
AstraZeneca cancer drug secures US approval
5 December 2024 08:48
(Sharecast News) - AstraZeneca drug Imfinzi has been approved for use in the US for patients with limited stage small cell lung cancer, the biopharmaceutical specialist confirmed on Thursday.
-
AstraZeneca appoints Iskra Reic as vice-president of intl unit
4 December 2024 14:00
(Sharecast News) - AstraZeneca said it had appointed AstraZeneca today announced the appointment of Iskra Reic as Executive Vice President (EVP), International with responsibility for overall strategy and...
-
AstraZeneca reports positive results from prostate cancer trial
25 November 2024 07:17
(Sharecast News) - AstraZeneca announced positive results from a phase three prostate cancer trial on Monday, reporting that its AKT inhibitor 'Truqap', or capivasertib, in combination with...
-
AstraZeneca's Tagrisso recommended for EU approval
18 November 2024 09:11
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its Tagrisso asset had received a recommendation for EU approval on the back of LAURA Phase III trial results, which revealed it had extended...
-
Sunday newspaper round-up: Kursk, AstraZeneca, BAE Systems
17 November 2024 18:14
(Sharecast News) - America's President has authorised Ukraine to employ long-range ATACMS supplied by the US to strike targets inside Russia. More specifically, Kyiv will now be allowed to strike...
-
Director dealings: AstraZeneca CEO ups stake
15 November 2024 16:11
(Sharecast News) - AstraZeneca revealed on Friday that chief executive officer Pascal Soriot had acquired 20,000 ordinary shares in the FTSE 100-listed drugmaker.
-
London close: Stocks end turbulent week in the red
15 November 2024 15:21
(Sharecast News) - London stocks ended Friday in negative territory, weighed down by losses in pharmaceutical shares and a surprise slowdown in UK economic growth during the third quarter.
Company announcements Announcements
-
Dato-DXd approved in US for HR+ breast cancer
20 January 2025 07:00
AstraZeneca
-
Calquence combination approved in US for 1L MCL
17 January 2025 07:00
AstraZeneca
-
Total Voting Rights
2 January 2025 15:00
AstraZeneca
-
Dato-DXd NSQ NSCLC application withdrawn in EU
24 December 2024 07:00
AstraZeneca
-
Tagrisso approved in EU based on LAURA trial
23 December 2024 07:00
AstraZeneca
-
Directorate Change
16 December 2024 07:00
AstraZeneca
-
Imfinzi approved in US for limited-stage SCLC
5 December 2024 07:00
AstraZeneca
-
AstraZeneca appoints Iskra Reic EVP International
4 December 2024 13:45
AstraZeneca
-
Block listing Interim Review
2 December 2024 15:05
AstraZeneca
-
Total Voting Rights
2 December 2024 15:00
AstraZeneca
-
Truqap improved rPFS in advanced prostate cancer
25 November 2024 07:00
AstraZeneca
-
Director/PDMR Shareholding
20 November 2024 16:00
AstraZeneca
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.